iiinova — where your digital self keeps evolving

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

3/3 💊 Rx pearl: 🟣 Micro: Gram-positive bacteria were most commonly treated, with limited gram-negative cases reported 💊 PO abx included amoxicillin, linezolid, levofloxacin, ciprofloxacin, TMP-SMX, & rifampin combinations Encouraging initial data, but further study needed #PedsIDsky #PedsRxsky

000

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

2/3 🧒💉 What was reported: 💉 IV-to-PO transition was evaluated in stable pediatric endocarditis patients 📋 8 patients transitioned to an oral step-down protocol ✅ 88% success rate reported A small but important signal for pediatric antimicrobial stewardship. #PedsIDsky #PedsRxsky

100

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

🔁 1/3 🧵 Rx Update | 🫀🧒 Pediatric Endocarditis 💬 ⚕️ By recent UConn Pharmacy grad Hira I. Can some stable pediatric endocarditis patients transition from IV to PO abxs? Early data suggest it may be promising, but more studies needed. Read more: pharmacy.uconn.edu/pediatric-id... #PedsIDsky #Rxsky

pharmacy.uconn.edu

Pediatric ID and Immunization Updates | UConn School of Pharmacy and Pharmaceutical Sciences | University of Connecticut

Resources for Pediatric ID and Immunization Updates for All Ages Mission: To provide healthcare professionals with timely, evidence-based insights in ...

100

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

3/3 🧴⚕️ Stewardship pearl: 📋 If AAP guideline adherence, Morin et al estimated a 19% decrease in abxs, or ~4.5 million days of therapy. 🥄 RX can help support AOM stewardship through education to help avoid unnecessary antibiotics when observation is appropriate. #PedsIDsky #PedsRxsky

000

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

2/3 🧒💊 Why this matters: Watchful waiting was associated with: 😣 Slight increase in pain before resolution 🏫 8 missed school days 🤒 Significant reductions in sick visits, adverse effects, and costs #PedsIDsky #PedsRxsky

100

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

🔁 1/3 🧵 Pharmacy Update | 🧸👂 Pediatric AOM Stewardship 💬 ⚕️ By recent UConn Pharmacy Grad Tim R. 👂 Watchful waiting in uncomplicated acute otitis media can be useful but remains underutilized. Read more: pharmacy.uconn.edu/pediatric-id... #PedsIDsky #PedsRxsky

pharmacy.uconn.edu

Pediatric ID and Immunization Updates | UConn School of Pharmacy and Pharmaceutical Sciences | University of Connecticut

Resources for Pediatric ID and Immunization Updates for All Ages Mission: To provide healthcare professionals with timely, evidence-based insights in ...

110

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

XFG is a JN.1-lineage SARS-CoV-2 variant based on review of variant surveillance, antigenic characterization, immunogenicity data, vaccine effectiveness data, and manufacturing feasibility. It is slightly different than last year's strain to help cover additional mutations. #PedsIDsky #PedsRxsky

000

Peds ID PharmD @pedsidpharmd.bsky.social · 08/06/2026

🧬 COVID-19 vaccine strain update for pharmacists: FDA has recommended th 2026-2027 COVID-19 vaccines for fall 2026 should be monovalent vaccines targeting the JN.1-lineage XFG variant. www.fda.gov/vaccines-blo... #PedsIDsky #PedsRxsky

fda.gov

COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beg

COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026

100

Reposted by Peds ID PharmD

CIDRAP @cidrap.bsky.social · 12/05/2026

Nirsevimab may protect babies from severe RSV better than maternal vaccination. But timing matters: When administered at least 8 weeks before delivery, maternal vaccination appears equally effective. Read more: ow.ly/weWR50YYsGE

Newborn baby in neonatal intensive care with medical tubes and sensors attached, receiving specialized treatment.

0237

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

10/10 🧵Key Takeaways: ✅ Oral therapy expands treatment options for adolescents ✅ Single-day or single-dose options may improve adherence ✅ MINIMIZE resistance: use only in proven or strongly suspected bacterial causes ⚠️ Still essential⚠️ Safe sexual practices, testing, and partner treatment

000

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

9/10 🧵Blujepa Trial Review Continued: • Noninferiority margin of 10% • Microbiological Cure Rate: - Gepotidacin: 92.6%, 95% CI 88–95.8 (n=187/202) - Comparator: 91.2%, 95% Cl 86.4–94.7 (n=186/204) - Difference: -0.1%, 95% CI -5.6–5.5

100

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

7/10 🧵💊Blujepa (gepotidacin)💊 Package Insert: shorturl.at/jp8dO •FDA approved for ≥ 45kg with limited or no alternative treatment options •MOA: bacterial type II topoisomerase inhibitor •Dose: 3g BID ×1 day with food •Warnings: QTc prolongation,acetylcholinesterase inhibition, and C. diff

shorturl.at

100

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

6/10 🧵 Nuzolvence Trial Review Continued: • Noninferiority margin of 12% - Authors’ reasoning: lack of treatments for MDR gonorrhea • Microbiological Cure Rate: - Zoliflodacin: 90.9%, 95% CI 88.1–93.3 (n=460/506) - Comparator: 96.2%, 92.9–98.3 (n=229/238) - Difference: 5.3%, 95% CI 1.4–8.6

100

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

4/10 🧵⚠️Nuzolvence Warnings & Precautions⚠️ •Notable adverse events: neutropenia, leukopenia, and C. diff •Utilize effective contraception for 3 months after administration •May cause fetal harm in pregnancy •May cause testicular toxicity and impair male fertility

100

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

3/10 🧵🍽️Nuzolvence Administration Considerations🍽️ *On empty stomach if <50 kg, with food if ≥50 kg* Why? 🧐 It has an inverse relationship between body weight and drug exposure. Patients who weigh less already get higher drug exposure, and food increases the AUC ~1.5-2x

100

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

2/10 🧵💊Nuzolvence (zoliflodacin)💊 Package Insert: shorturl.at/ruf6S FDA approved for uncomplicated urogenital gonorrhea for patients ≥35 kg •MOA: bacterial type II topoisomerase inhibitor •Dose: single 3g in 60mL water (use within 15 min)

shorturl.at

100

Peds ID PharmD @pedsidpharmd.bsky.social · 07/04/2026

🔁1/10 🧵 Pharmacy Update | 💬 ⚕️ By UConn P4 Nicole P 🚨 FDA Update (Dec 2025)🚨 Two new ORAL antibiotics, Nuzolvence (zoliflodacin) & Blujepa (gepotidacin), are now approved for uncomplicated urogenital gonorrhea in patients ≥12 years old FDA News Release: shorturl.at/E0CpI

shorturl.at

FDA Approves Two Oral Therapies to Treat Gonorrhea

The U.S. Food and Drug Administration recently approved two new oral medicines to treat a common sexually transmitted infection called gonorrhea.

120

Reposted by Peds ID PharmD

PIDS @pidsociety.bsky.social · 16/03/2026

PIDS applauds today’s momentous federal court finding that the dismissal and reconstitution of the ACIP and anomalous changes made by the Secretary of Health and Human Services to the childhood immunization schedule were likely unlawful. Statement: pids.org/2026/03/16/p...

094

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

Note these components are all different than what was included in the 2025-2026 flu vaccines.

010

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

Cell and Recombinant 2026-2027 influenza vaccine components: - A/Missouri/11/2025(H1N1)pdm09-like virus; - A/Darwin/1454/2025(H3N2)-like virus; - B/Pennsylvania/14/2025 (B/Victoria lineage)

000

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

Egg Based 2026-2027 influenza vaccine components: - A/Missouri/11/2025(H1N1)pdm09-like virus; - A/Darwin/1454/2025(H3N2)-like virus; - B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus

100

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

🧵FDA advisory committee has voted to recommend the following components for the 2026-2027 influenza vaccines

100

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

FDA having their influenza vaccine advisory committee meeting today to vote on products for the 2026-2027 season. This will also include information on current vaccine effectiveness and likely circulating strains. Meeting live at www.youtube.com/live/WKw0WEi...

youtube.com

YouTube video by U.S. Food and Drug Administration

100

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

New Literature 12/2025: Clinical Trial HPV 1 vs 2 dose series Population: Girls 12-16 y/o in Puerto Rico (n= 20,330) Results: Non-inferiority of 1 vs 2 doses; Difference of 0.21 infections/100 persons (95% CI, -0.09 to 0.51; P<0.001) pubmed.ncbi.nlm.nih.gov/41337735/ #PedsIDsky #RXsky

pubmed.ncbi.nlm.nih.gov

Noninferiority of One HPV Vaccine Dose to Two Doses - PubMed

One dose of either a bivalent or nonavalent HPV vaccine provided protection against HPV16 or HPV18 infection and was not inferior to two doses. (Funded by the National Cancer Institute and others; ESCUDDO ClinicalTrials.gov number, NCT03180034.).

100

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

Guideline Recommendations for Healthy Pediatrics AAP: 9-14 y/o- 2 doses, (if beginning series at >15 y/o- 3 doses recommended) CDC: 1 dose at 11-12 y/o WHO: 1-2 doses at 9-14 y/o #PedsIDsky #RXsky

100

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

HPV Vaccination 88% decrease in HPV infections among 14-19 y/o females since vaccine introduction in 2006 Available product: (Gardasil 9) nonavalent vaccine Immunization can protect against HPV infection and related cancers #PedsIDsky #RXsky

100

Peds ID PharmD @pedsidpharmd.bsky.social · 12/03/2026

🔁 🧵 Pharmacy Update | UConn P4 HPV Immunization Review 💬 ⚕️💉 By Megan.

100

Peds ID PharmD @pedsidpharmd.bsky.social · 04/03/2026

Another recent publication w/the PPA Immunization Committee, we highlight the importance of the hepatitis B vaccine at birth. 👶💉 🔗 jppt.kglmeridian.com/view/journal... #PedsIDsky #Rxsky

jppt.kglmeridian.com

000

Peds ID PharmD @pedsidpharmd.bsky.social · 04/03/2026

Here is is our PPA Immunization Committee publication to support pharmacists in immunization practice. 💉📚 This article provides evidence-informed strategies and practical resources to strengthen vaccine conversations with families. 🔗 jppt.kglmeridian.com/view/journal... #PedsIDsky #Rxsky

jppt.kglmeridian.com

000

Reposted by Peds ID PharmD

JAMA @jama.com · 29/12/2025

💬 Perspective: The rise of H3N2 subclade K may increase severe #influenza outcomes this season; available vaccines and antivirals remain important tools for prevention and treatment. ja.ma/3MVJMt1

A JAMA article titled "Influenza A(H3N2) Subclade K Virus Threat and Response" shows diagrams of the influenza virus, highlighting antigenic sites and amino acid changes. Labels indicate receptor-binding sites and glycosylation sites.

073

Peds ID PharmD @pedsidpharmd.bsky.social · 19/12/2025

4️⃣ 🚨 Treat early! Antivirals recommended for: ✔️ High-risk patients (incl children <2 / <5 yrs and adults ≥65 yrs) ✔️ Chronic medical conditions ✔️ Progressive disease ✔️ All hospitalized patients 🔗 Who is high risk? www.cdc.gov/flu/highrisk... #PedsIDsky #RXsky

cdc.gov

People at Increased Risk for Flu Complications

Learn more about who is at higher risk of developing potentially serious flu complications.

000

Peds ID PharmD @pedsidpharmd.bsky.social · 19/12/2025

3️⃣ 🦠 Influenza A (H3N2) predominates ➡️ ~90% of subtyped isolates ( ~90% of these = K subtype) Luckily! 💊 All tested strains remain susceptible to neuraminidase inhibitors (e.g., oseltamivir) and baloxavir #PedsIDsky #RXsky

100

Peds ID PharmD @pedsidpharmd.bsky.social · 19/12/2025

2️⃣ 🌎 High / very high flu activity in ~1/3 of states 📍 Southern New England, NY, NJ, LA, CO, ID, MI, SC 👶📊 Highest outpatient/ED flu visits in younger age groups #PedsIDsky #RXsky

100

Peds ID PharmD @pedsidpharmd.bsky.social · 19/12/2025

🧵 CDC FluView Update (12/19) 📈 Flu activity is rising: 2nd week above baseline 🤒 ILI ~4% nationwide 🧪 Flu test positivity ↑ ~15% this week 🔗 CDC FluView Week 50: www.cdc.gov/fluview/surv... #PedsIDsky #RXsky

cdc.gov

Weekly US Influenza Surveillance Report: Key Updates for Week 50, ending December 13, 2025

Seasonal influenza activity is low.

130

Peds ID PharmD @pedsidpharmd.bsky.social · 09/12/2025

📢 In a time where vaccine hesitancy is rising, the Pediatric Pharmacy Association’s Immunization Committee has published guidance on how to build immunization confidence through communication, education, and trusted resources. Read more here: jppt.kglmeridian.com/view/journal... #Rxsky

jppt.kglmeridian.com

020

Reposted by Peds ID PharmD

Madhu Pai, MD, PhD @madhupai.bsky.social · 05/12/2025

Grateful for the clear messages coming from @ameracadpeds.bsky.social @idsainfo.bsky.social @apha.org

27731

Reposted by Peds ID PharmD

The American Academy of Pediatrics @ameracadpeds.bsky.social · 05/12/2025

The decision by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention to downgrade its recommendations to protect infants from hepatitis B is a dangerous move that will harm children. Click here to read AAP's full statement: bit.ly/3Y9ZQJT

351178640

Reposted by Peds ID PharmD

Jon Mosser @jonmosser.com · 05/12/2025

#ACIP votes to change the #hepatitisB #vaccine birth dose recommendation, ending the universal birth dose policies that have almost eliminated neonatal hepatitis B infection, cut pediatric infections by more than 95%, and prevented more than 6 million infections / a million hospitalizations.

cidrap.umn.edu

New review finds no evidence to support delaying universal hepatitis B birth-dose vaccination

124

Reposted by Peds ID PharmD

Helen Branswell 🇨🇦 @helenbranswell.bsky.social · 04/12/2025

It's hard to predict what the new #ACIP will do, but it looks like it will recommend that the universal birth dose for #hepatitisB be jettisoned. Experts warn even a delay of 2 months before the first dose will lead to chronically infected kids & deaths. www.statnews.com/2025/12/04/c...

statnews.com

CDC vaccine advisers appear likely to recommend delaying hepatitis B vaccine birth dose

A panel that issues advice on U.S. vaccine policy appears prepared to vote Thursday to recommend a delay in when most babies begin to be vaccinated against hepatitis B.

27736

Peds ID PharmD @pedsidpharmd.bsky.social · 05/12/2025

ACIP meeting is about to start. The updated proposed HepB vote language has been posted. www.cdc.gov/acip/meeting... This language is confusing and if passed will result in more infants exposed.

cdc.gov

Next ACIP Meeting: Anticipated Votes

Read draft vote language to be considered during the next ACIP meeting.

020

Peds ID PharmD @pedsidpharmd.bsky.social · 04/12/2025

The vote was slightly different than what was published and was delayed until tomorrow so members were able to fully review the updated options and language before voting.

010

Reposted by Peds ID PharmD

Voices for Vaccines @voices4vaccines.bsky.social · 04/12/2025

A study cited in today's ACIP meeting about Hep B and SIDS was misrepresented. The study's authors themselves have refuted an association.

False claims often link childhood vaccines, including the hepatitis B (HBV) vaccine, to sudden
infant death syndrome (SIDS). In reality, many studies have looked at this issue and found no
connection between vaccines and SIDS. While most studies examined the full set of childhood
vaccines rather than HBV alone, at least one study focused just on HBV and still found no link.
During this meeting, the ACIP committee is likely to cite this study which at first glance seemed
to have found a higher rate of SIDS deaths in the vaccinated group, but the total overall number
of unexpected infant deaths due to any cause was not statistically significantly different between
HBV vaccinated and unvaccinated groups (p=0.6). In the initial analysis, they looked at deaths
of infants who had received the Hep B vaccine. In this group, there were 8 SIDS deaths. By
contrast, the group of infant deaths in the matched unvaccinated group that was used for
comparison had no SIDS deaths, but did have a lot of other causes of death.
This initial imbalance likely reflects confounding: the matched unvaccinated infants were more
medically fragile or unhealthy overall, and at higher risk for mortality from other causes, making
them an inappropriate comparison group.
To address this, the authors calculated SIDS rates using the full population—240,717
vaccinated infants (including the 8 SIDS deaths mentioned above, 3.3 per 100,000 births), and
120,979 unvaccinated newborns (including four additional SIDS cases not captured in the
matched subset, also 3.3 per 100,000 births). The resulting identical rates (P = 0.99) show
no statistical difference in SIDS risk between HBV vaccinated and unvaccinated
newborns.

0158

Reposted by Peds ID PharmD

Your Local Epidemiologist @ylepidemiologist.bsky.social · 04/12/2025

If anyone is looking for a bit more in depth info on the HBV vaccine, you may find this helpful www.cidrap.umn.edu/vaccine-inte...

cidrap.umn.edu

Vaccine Integrity Project - Hepatitis B

1178